Loading…
← CockpitCompetitor Analysis › ACAD ACADIA Pharmaceuticals Inc.Open in the cockpit ↗

ACADIA Pharmaceuticals Inc.ACADCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Makes Nuplazid for Parkinson's-disease psychosis and Daybue for Rett syndrome, with a CNS-focused pipeline.

Momentum weak 20
Mkt cap
$3.08B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$52.7M
20-day average traded
Fwd P/E
17.8×
forward earnings
ROIC−WACC
+10.7 pp
WACC 9.3%
Hurdle
-10 pp
Req g minus delivered
Next earnings
103 days
1 Mar 2027
Close · USD$17.83
1D-2.7%
1W-2.9%
1M-12.8%
3M-38.6%
6M-14.9%
YTD-33.2%
1Y-25.7%
ATR %5.6%
Beta0.34
52w lowhigh42.4% off high

What ACADIA Pharmaceuticals does

Makes Nuplazid for Parkinson's-disease psychosis and Daybue for Rett syndrome, with a CNS-focused pipeline.

Sells both drugs in the US through specialty pharmacies, paid prescription by prescription by insurers. Nuplazid, on sale since 2016, carries most of the revenue, and Daybue, launched in 2023, is the newer line. Daybue is licensed from Neuren Pharmaceuticals, to which Acadia pays royalties.

Products and services

  • Nuplazid (Parkinson's psychosis)
  • Daybue (Rett syndrome)
  • CNS pipeline

Customers

  • Neurologists/psychiatrists
  • Rare-disease specialists

Where it sits in the supply chain

  • CNS pharmaceuticals
  • Neuropsychiatric drug development
  • Commercial specialty-drug sales

What could go right

  • Daybue launch ramp
  • New CNS pipeline readouts

What could go wrong

  • Nuplazid patent-cliff/generic risk
  • Payer/reimbursement pressure on rare-disease drugs

Moat: narrow (IP / patents, regulatory licence). Orphan-drug exclusivity and being first-approved in each indication limit near-term competition.

Headquarters: San Diego, California, US · Founded: 1993 · Employees: 798

Named competitors

ACADIA Pharmaceuticals at a glance

Size ACADIA Pharmaceuticals (ACAD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.08B, the 1522nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.83 on 18 Nov 2026.

Performance Over six months the shares fell 14.9%, against +1.9% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 14.8% over the last twelve months (peer median +25.3%); the operating margin is 10.2% (peer median 14.8%).

Valuation It trades at 17.8× forward earnings against a peer median of 22.1× (6th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 10.7 points above its cost of capital (9.3% WACC).

Short interest Short interest is 4.8% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 104ACAD 84
Six months, rebased to 100: ACADIA Pharmaceuticals against the median of its 20 peers (local-currency closes).

ACADIA Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.20B$1.07B$958M$726M$517M
Revenue growth—+12%+32%+40%—
Gross profit$1.09B$972M$861M$681M$507M
EBITDA$135M$117M$100M-$67.8M-$222M
Net income$362M$391M$226M-$61.3M-$216M
Free cash flow$82.0M$105M$157M$16.7M-$114M
Capital expenditure$15.5M$104M$523,000$40.0M$0
Total debt$71.9M$52.2M$52.0M$57.2M$62.0M

Quarterly statements and history in the cockpit →

ACADIA Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%2696LEGN688266VCEL0027736005350867NEULANDLAB600380VKTX000739PPLPHARMA2096VRDNAMLX002262688180ARQTACUTAASACAD6-month return →1-month return →
Up and to the right = strong over both horizons. ACADIA Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×2696LEGN688266VCEL0027736005350867NEULANDLAB600511000739PPLPHARMA2096ARQTACUTAASACADRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ACADIA Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%2696688266VCEL002773600535ARQTACADGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ACADIA Pharmaceuticals is the large dot.

ACADIA Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (ACAD vs NBIX vs SUPN vs BIIB)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
ACADIA Pharmaceuticals ACAD$3.08B-15%+15%10%17.8×9.2%
Neurocrine Biosciences NBIX$16.5B+5%+38%25%18.0×-1.5%
Supernus Pharmaceuticals SUPN$6.02B-41%+16%45%8.0×6.2%
Biogen BIIB$37.2B+34%+2%17%17.1×10.1%
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%9.3×-2.8%

How ACADIA Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ACADIA Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureACADPeer medianRank in peer set
1-month return-12.8%-0.1%5th lowest of 21
6-month return-14.9%+1.9%6th lowest of 21
Distance from 52-week high-42.4%-19.4%5th lowest of 21
Revenue growth (TTM)+14.8%+25.3%10th lowest of 20
Operating margin10.2%14.8%9th lowest of 19
Forward P/E17.8×22.1×6th cheapest of 17
Growth the price implies (Req g, 7 yrs)9.2%-0.5%5th most demanding of 13
Growth delivered (Del g)+19.4%+8.8%4th highest of 13
Hurdle (Req g minus delivered)-10.1 pp-14.0 pp5th most demanding of 13
ROIC minus cost of capital+10.7 pp+5.7 pp6th highest of 17
EV / EBITDA16.1×30.7×3rd cheapest of 10
Net debt / EBITDA-6.7×-0.8×2nd least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a

Questions

Who are ACADIA Pharmaceuticals's main competitors?
Named competitors: Neurocrine Biosciences (NBIX), Supernus Pharmaceuticals (SUPN), Biogen (BIIB), Jazz Pharmaceuticals (JAZZ). The cockpit's measured peer set (industry) also includes Shanghai Henlius Biotech (2696.HK), Legend Biotech Corp. Sponsored ADR (LEGN), Suzhou Zelgen Biopharmaceuticals (688266.SS), Vericel (VCEL), Chengdu Kanghong Pharmaceutical (002773.SZ), Tasly Pharmaceutical (600535.SS).
Is ACADIA Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 17.8× against a peer median of 22.1×, 6th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has ACADIA Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -14.9% against +1.9% for the median peer; over one year -25.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.